<DOC>
	<DOCNO>NCT01049126</DOCNO>
	<brief_summary>The purpose study ass relationship assay sensitive patient versus assay resistant patient progression free survival .</brief_summary>
	<brief_title>Retrospective Case Study Examining Patient Outcomes Compared ChemoFx Assay Endometrial Cancer Patients</brief_title>
	<detailed_description>This multicenter , retrospective chart review study de-identified drug response marker result limit data set clinical outcome data . Data approximately 70 case collect approximately 10 study site correlate ChemoFx drug response marker result . The outcome progression free survival define period time first dose chemotherapy follow report marker result clinical progression death . Objective response measure first dose chemotherapy follow report marker result progression change therapy . Overall Survival measure start chemotherapy actual date death .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Case original pathology report show stage III , IIIa , IIIb , IIIc , IV , IVa , IVb , recurrent endometrial cancer . Case include pathology cytology report initial diagnosis show disease one follow histologic epithelial cell type : serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , transitional cell carcinoma , clear cell carcinoma , adenocarcinoma , otherwise specify ( N.O.S. ) . Case identify pattern response evaluation . Case must commercial ChemoFx drug response marker final report . Cases patient decease prior 1 cycle chemotherapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Late Stage</keyword>
</DOC>